• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中轴型脊柱关节炎患者整体功能改善的预测因素

Predictors for Improvement of Global Functioning in Patients with Axial Spondyloarthritis.

作者信息

Kang Kwi Young, Adler Brittany L, Chung Tae Hwan

机构信息

Department of Physical Medicine and Rehabilitation, Johns Hopkins University, Baltimore, MD 21224, USA.

Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

出版信息

J Clin Med. 2025 Jun 24;14(13):4474. doi: 10.3390/jcm14134474.

DOI:10.3390/jcm14134474
PMID:40648848
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12249854/
Abstract

: We aimed to investigate the factors associated with changes in the global functioning of patients with axial spondyloarthritis (axSpA) and to identify predictors of improvement. : One-hundred-and-eighty-five patients enrolled in the Incheon Saint Mary's axSpA prospective observational cohort were evaluated. Global functioning was assessed at baseline and at 1-year follow-up using the ASAS health index (HI). Improvement was defined as a reduction in the ASAS HI of ≥3. Physical function was assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI). Disease activity measures included Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS), and C-reactive protein (CRP) levels. Predictors of improved global functioning were identified by logistic regression analysis. : Nineteen patients (10%) showed improved global functioning at 1-year follow-up versus baseline. Univariate linear regression analysis identified body mass index at baseline, the use of TNF inhibitors, a change in the BASFI and BASDAI, and changes in CRP levels as being associated with changes in the ASAS HI. Multivariate analysis revealed that changes in the BASFI and BASDAI were associated independently with a change in the ASAS HI. Univariate logistic regression analysis revealed that a decrease in the BASFI, BASDAI, ASDAS, and CRP levels predicted improved global functioning. Multivariate analysis identified a decrease in the BASFI and BASDAI as a significant predictor of improved global functioning (odds ratio (95% CI) = 1.465 (1.006-2.135) and 1.414 (1.044-1.914), respectively). : Changes in physical function and disease activity were associated independently with changes in global functioning assessed by the ASAS HI in axSpA. A decrease in the BASFI and BASDAI was a significant predictor of improvement in the ASAS HI.

摘要

我们旨在研究与中轴型脊柱关节炎(axSpA)患者整体功能变化相关的因素,并确定改善的预测指标。对185名纳入仁川圣母医院axSpA前瞻性观察队列的患者进行了评估。使用强直性脊柱炎协会健康指数(HI)在基线和1年随访时评估整体功能。改善定义为强直性脊柱炎协会HI降低≥3。使用巴斯强直性脊柱炎功能指数(BASFI)评估身体功能。疾病活动指标包括巴斯强直性脊柱炎疾病活动指数(BASDAI)、强直性脊柱炎疾病活动评分(ASDAS)和C反应蛋白(CRP)水平。通过逻辑回归分析确定整体功能改善的预测指标。19名患者(10%)在1年随访时与基线相比整体功能有所改善。单变量线性回归分析确定基线时的体重指数、TNF抑制剂的使用、BASFI和BASDAI的变化以及CRP水平的变化与强直性脊柱炎协会HI的变化相关。多变量分析显示,BASFI和BASDAI的变化与强直性脊柱炎协会HI的变化独立相关。单变量逻辑回归分析显示,BASFI、BASDAI、ASDAS和CRP水平的降低预示着整体功能的改善。多变量分析确定BASFI和BASDAI的降低是整体功能改善的重要预测指标(优势比(95%CI)分别为1.465(1.006 - 2.135)和1.414(1.044 - 1.914))。在axSpA中,身体功能和疾病活动的变化与通过强直性脊柱炎协会HI评估的整体功能变化独立相关。BASFI和BASDAI的降低是强直性脊柱炎协会HI改善的重要预测指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c56d/12249854/dba793251f91/jcm-14-04474-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c56d/12249854/dba793251f91/jcm-14-04474-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c56d/12249854/dba793251f91/jcm-14-04474-g001.jpg

相似文献

1
Predictors for Improvement of Global Functioning in Patients with Axial Spondyloarthritis.中轴型脊柱关节炎患者整体功能改善的预测因素
J Clin Med. 2025 Jun 24;14(13):4474. doi: 10.3390/jcm14134474.
2
Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).用于中轴型脊柱关节炎(强直性脊柱炎和非放射学中轴型脊柱关节炎)的非甾体抗炎药
Cochrane Database Syst Rev. 2015 Jul 17;2015(7):CD010952. doi: 10.1002/14651858.CD010952.pub2.
3
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.阿达木单抗、依那西普和英夫利昔单抗治疗强直性脊柱炎:系统评价与经济学评估
Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. doi: 10.3310/hta11280.
4
Preliminary definitions of 'flare' in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative.基于疼痛、BASDAI 和 ASDAS-CRP 的中轴型脊柱关节炎“ flares ”的初步定义:ASAS 倡议。
Ann Rheum Dis. 2016 Jun;75(6):991-6. doi: 10.1136/annrheumdis-2015-208593. Epub 2016 Feb 4.
5
Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation.用于强直性脊柱炎和非放射学中轴型脊柱关节炎的肿瘤坏死因子-α抑制剂:一项系统评价和经济学评估
Health Technol Assess. 2016 Feb;20(9):1-334, v-vi. doi: 10.3310/hta20090.
6
Efficacy of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level.依奇珠单抗在基线C反应蛋白水平不同的中国放射学阳性中轴型脊柱关节炎患者中的疗效
Rheumatol Ther. 2025 May 9. doi: 10.1007/s40744-025-00765-7.
7
The validity and reliability of quality of life questionnaires in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and meta-analysis.强直性脊柱炎和非放射学中轴型脊柱关节炎患者生活质量问卷的有效性和可靠性:系统评价和荟萃分析。
Health Qual Life Outcomes. 2022 Jul 30;20(1):116. doi: 10.1186/s12955-022-02026-5.
8
TNF-alpha inhibitors for ankylosing spondylitis.用于强直性脊柱炎的肿瘤坏死因子-α抑制剂
Cochrane Database Syst Rev. 2015 Apr 18;2015(4):CD005468. doi: 10.1002/14651858.CD005468.pub2.
9
Predictors of remission in people with axial spondyloarthritis: A systematic literature review.轴性脊柱关节炎患者缓解的预测因素:系统文献回顾。
Semin Arthritis Rheum. 2022 Oct;56:152078. doi: 10.1016/j.semarthrit.2022.152078. Epub 2022 Jul 27.
10
Effects of a Digital Functional Exercise Program on the Disease Activities and Physical Capabilities of Patients With Ankylosing Spondylitis: Protocol for a Randomized Controlled Trial.数字功能锻炼计划对强直性脊柱炎患者疾病活动度和身体能力的影响:一项随机对照试验方案
JMIR Res Protoc. 2025 Jul 7;14:e67556. doi: 10.2196/67556.

本文引用的文献

1
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.ASAS-EULAR 推荐的中轴型脊柱关节炎管理:2022 更新。
Ann Rheum Dis. 2023 Jan;82(1):19-34. doi: 10.1136/ard-2022-223296. Epub 2022 Oct 21.
2
The Sensitivity to Change of the ASAS Health Index in an Observational Real-Life Cohort Study.一项观察性真实生活队列研究中ASAS健康指数对变化的敏感性
J Rheumatol. 2023 Feb;50(2):185-191. doi: 10.3899/jrheum.220212. Epub 2022 Aug 1.
3
Deep Insight into the Role of MIF in Spondyloarthritis.深入了解巨噬细胞移动抑制因子在脊柱关节炎中的作用。
Curr Rheumatol Rep. 2022 Sep;24(9):269-278. doi: 10.1007/s11926-022-01081-7. Epub 2022 Jul 9.
4
Instrument selection for the ASAS core outcome set for axial spondyloarthritis.用于评估中轴型脊柱关节炎的 ASAS 核心结局集的工具选择。
Ann Rheum Dis. 2023 Jun;82(6):763-772. doi: 10.1136/annrheumdis-2022-222747. Epub 2022 Jun 9.
5
Effects of patient and disease characteristics on global functioning in patients with axial spondyloarthritis in routine care.在常规治疗中,患者和疾病特征对轴性脊柱关节炎患者的整体功能的影响。
Semin Arthritis Rheum. 2022 Aug;55:152006. doi: 10.1016/j.semarthrit.2022.152006. Epub 2022 Apr 15.
6
The ASAS Health Index: A New Era for Health Impact Assessment in Spondyloarthritis.ASAS 健康指数:脊柱关节炎健康影响评估的新纪元。
J Rheumatol. 2022 Jan;49(1):8-15. doi: 10.3899/jrheum.200586. Epub 2021 Aug 15.
7
Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial.靶向治疗紧密控制策略在中轴型脊柱关节炎中的疗效:开放标签、实用、群组随机 TICOSPA 试验的结果。
Ann Rheum Dis. 2021 Nov;80(11):1436-1444. doi: 10.1136/annrheumdis-2020-219585. Epub 2021 May 6.
8
ASAS Health Index as an Addition to Routine Clinical Practice.
J Rheumatol. 2021 May;48(5):787. doi: 10.3899/jrheum.201440. Epub 2021 Jan 15.
9
Use of multidimensional composite scores in rheumatology: parsimony versus subtlety.在风湿病学中使用多维综合评分:简约与微妙。
Ann Rheum Dis. 2021 Mar;80(3):280-285. doi: 10.1136/annrheumdis-2020-216999. Epub 2020 Nov 3.
10
Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial.在一项 52 周、随机、对照试验中,使用依奇珠单抗治疗活动性非放射性轴性脊柱关节炎可改善功能和健康状况。
Arthritis Care Res (Hoboken). 2022 Mar;74(3):451-460. doi: 10.1002/acr.24482. Epub 2022 Jan 26.